LENZ Therapeutics, Inc. (LENZ)
2025-06-30 | ||||
|---|---|---|---|---|
| Revenue | 5 | |||
| Selling, general and administrative | 12.796 | |||
| Research and development | 9.061 | |||
| Total operating expenses | 21.857 | |||
| Loss from operations | -16.857 | |||
| Other income | 0.199 | |||
| Interest income | 2.246 | |||
| Total other income, net | 2.445 | |||
| Net loss before income taxes | -14.412 | |||
| Income tax expense | 0.5 | |||
| Net loss | -14.912 | |||
| Unrealized loss on marketable securities | -0.085 | |||
| Comprehensive loss | -14.997 | |||
| Net loss per share - basic (in dollars per share) | -0.53 | |||
| Net loss per share - diluted (in dollars per share) | -0.53 | |||
| Weighted-average common shares outstanding, basic (in shares) | 28,079,071 | |||
| Weighted-average common shares outstanding, diluted (in shares) | 28,079,071 | |||